drugset / Trial / NCT05546047

A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients

NCT05546047

Phase 4 Unknown 34 enrolled NephroNet, Inc. Mallinckrodt · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A Multicenter, Comparative Safety and Efficacy Study of Acthar gel alone or in combination with oral Tacrolimus to reduce urinary proteinuria in patients with idiopathic DNAJB9 Positive Fibrillary glomerulopathy.

Timeline

Start
2019-03-14
Primary completion
2023-10-27
Completion
2024-10-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acthar Peptide 80 iu
Comparator Tacrolimus Small molecule 1 mg Oral